摘要
目的评价树突状细胞-细胞因子诱导的杀伤细胞(DC-CIK)治疗异基因造血干细胞移植后复发的急性髓系白血病(AML)的安全性和临床疗效。方法回顾性分析进行DC-CIK治疗的经异基因造血干细胞移植后复发的23例AML患者,血液学复发患者接受标准化疗联合DC-CIK方案,分子生物学复发患者接受DC-CIK单药治疗,治疗后观察分析患者的完全缓解率(CRR)、移植物抗宿主病(GVHD)发生率、总体生存期(OS)、无进展生存期(PFS)和不良事件等。结果与结论所有患者输注细胞时,均无发热及过敏等严重不良反应发生。细胞治疗后急性GVHD累积发生率为34.8%(8/23),慢性GVHD累积发生率为15.0%(3/20),均未发生Ⅱ度以上急性GVHD。23例患者经DC-CIK治疗后,CRR为60.9%(14/23),总体缓解率(ORR)65.2%(15/23),5年OS为39.1%(9/23),5年PFS生存率30.4%(7/23)。DC-CIK治疗对分子生物学复发和血液学复发的AML患者的疗效无统计学差异(P>0.05)。DC-CIK细胞用于治疗移植后复发的AML患者安全、有效。
Objective To evaluate the safety and clinical efficacy of DC-CIK cells in the treatment of recurrent acute myeloid leukemia(AML)after allogeneic hematopoietic stem cell transplantation(allo-HSCT). Methods Clinical data on 23 AML patients who relapsed after allogeneic hematopoietic stem cell transplantation and were treated with dendritic cells-cytokine-induced killer cells(DC-CIK)was analyzed retrospectively. Patients with hematological relapse received standard chemotherapy combined with DC-CIK cells,while those with molecular biological relapse received DC-CIK cells alone. The main observation indexes were CR,graft versus host disease(GVHD),OS,PFS and adverse events. Results and Conclusion None of the patients had any serious adverse reactions such as fever or allergy when infused with cells.The incidence of acute GVHD was 34.8%(8/23),and that of chronic GVHD was 15.0%(3/20). No acute GVHD above Ⅱdegree occurred after cell therapy. For the 23 patients treated with DC-CIK,the CR rate was 60.9%(14/23),the 5-year survival rate was 39.1%(9/23),and the 5-year progression-free survival rate was 30.4%(7/23). In terms of the efficacy of DC-CIK cells in the treatment of AML patients with molecular biological relapse and hematological relapse,there was no significant difference(P>0.05). DC-CIK cell therapy is safe and effective for patients with relapsed AML after allo-HSCT.
作者
于航
吉九阳
徐晨
王军
李欲航
扈江伟
苏永锋
王丹红
胡亮钉
孙耀
宁红梅
YU Hang;JI Jiu⁃yang;XU Chen;WANG Jun;LI Yu⁃hang;HU Jiang⁃wei;SU Yong⁃feng;WANG Dan⁃hong;HU Liang⁃ding;SUN Yao;NING Hong⁃mei(Department of Hematopoietic Stem Cell Transplantation,Fifth Medical Center,General Hospital of PLA,Beijing 100071,China)
出处
《军事医学》
CAS
北大核心
2020年第8期599-604,共6页
Military Medical Sciences
基金
首都临床特色应用研究与推广项目(Z161100000516184)
